drugset
drugset / Trial / NCT07535775

Evaluate Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 After Single Subcutaneous Injection in Healthy Chinese Volunteers

NCT07535775 ↗

Phase 1 Active not recruiting 48 enrolled SPH-BIOCAD (HK) Limited
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of BCD-261 after Single Subcutaneous Injection in Healthy Chinese Volunteers

Timeline

Start
2026-05-11
Primary completion
2026-10-10
Completion
2027-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject BCD-261 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.